6505--Rituximab and Biosimilars
Closed Pre-Solicitation Posted
This opportunity was awarded. See the award notice from , or the latest solicitation from .
- Solicitation number
- 36E79725R0021
- Agency
- National Acquisition Center Headquarters, Department of Veterans Affairs
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Points of contact
-
- Deb Fassl deborah.fassl@va.gov (708) 786-5894
Notice details come from SAM.gov. Updated .
About this opportunity
The VA National Acquisition Center intends to issue a Request for Proposal (RFP) 36E79725R0021 for Rituximab and its biosimilars, targeting multiple federal healthcare agencies including the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The procurement is unrestricted and will award one contract to a responsible offeror capable of providing an uninterrupted supply of the specified pharmaceuticals. Offerors must provide the exact drug name as it appears on the label and include a unique NDC number. The solicitation will be electronically issued on February 17, 2025, with a tentative closing date of March 4, 2025, and all documents will be available on SAM.gov. Potential bidders can submit questions to the point of contact, Deb Fassl, at Deborah.Fassl@va.gov, and must ensure any proposed biosimilar products are FDA-licensed under 42 U.S.C 262 and listed in the FDA Purple Book.
The contract will have a base period of one year with four additional pre-priced one-year option periods, distributed through the VA's Pharmaceutical Prime Vendor Program. The estimated annual requirements include 17,858 vials of 10ML Rituximab/biosimilars and 25,111 vials of 50ML Rituximab/biosimilars, categorized under NAICS code 325412 for Pharmaceutical Preparation Manufacturing. No specific set-aside has been designated for this procurement, indicating it is open to all qualifying vendors. The solicitation follows Federal Acquisition Regulation (FAR) Part 12 for commercial product procurement, and interested parties are advised to continuously monitor SAM.gov for any amendments or updates. No paper copies of the solicitation will be available, and all responses must be submitted electronically by the specified deadline.
Notice text
PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79725R0021 for an unrestrictive procurement for Rituximab for the Department of Veterans Affairs (VA) (inclusive of Consolidated Mail Order Pharmacies (CMOPs) and Option 2 State Veterans Homes (SVH)), Department of Defense (DoD), Bureau of Prisons (BoP), Indian Health Service (IHS), and Federal Health Care Center (FHCC).The VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted item. The contract period will be for one year plus four pre-priced one-year option periods. The contract item(s) will be distributed through the VA s Pharmaceutical Prime Vendor Program. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. Solicitation 36E79725R0021 will be electronically issued in commercial product format in accordance with FAR Part 12 on or about February 17, 2025, with a tentative closing date of March 4, 2025. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at the following URL: www.sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check this URL for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Deb Fassl. Questions can be e-mailed to: Deborah.Fassl@va.gov.
The estimated annual requirement is as follows:
ITEM
DESCRIPTION
PKG SIZE
(ML per Vials)
TOTAL ESTIMATED ANNUAL USAGE
(Vials)
1
RITUXIMAB 10MG/ML AND BIOSIMILARS*
10
17,858
2
RITUXIMAB 10MG/ML AND BIOSIMILARS*
50
25,111
*Proposed biosimilar products must be biological products licensed by the FDA under 42 U.S.C § 262 and must meet all biosimilar criteria described in 42 U.S.C. § 262. Additionally, Biosimilars Products must be FDA approved as a biologic medication that is compared to the innovator (the original biologic) and listed as a biosimilar to the innovator in the FDA Purple Book (https://purplebooksearch.fda.gov/).
Attachments
| File | Type | Posted |
|---|---|---|
| 36E79725R0021_1.docx | DOCX document |
Notice history
| Notice | Type | Posted |
|---|---|---|
| 6505--Rituximab Effective 09/15/2025 - 09/14/2026 | Award Notice | |
| 6505--Rituximab and Biosimilars | Solicitation | |
| 6505--Rituximab and Biosimilars | Pre-Solicitation |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity